Head-to-head evidence
BMF-500 vs Quizartinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Acute Myeloid Leukemia
Shared mechanism: FLT3 · full Acute Myeloid Leukemia pipeline
BMF-500
Developed by Biomea Fusion
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Quizartinib
Marketed by Daiichi Sankyo
NCT02668653 · Phase 3 · completed
The trial randomized 539 participants to quizartinib plus chemotherapy or placebo plus chemotherapy, with participants, investigators, and outcome assessors masked. Its hard primary endpoint, overall survival, was met in favor of quizartinib, with a statistically significant hazard ratio of 0.776 (p=0.0324).
Next expected readout: May 2027 · NCT03793478 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BMF-500's landscape · Quizartinib's landscape